MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients

Neoplasia (United States)

Volumn 14, Issue 12, 2012, Pages 1144-1152

  Gámez Pozo, Angelo ^a   Antón Aparicio, Luis M ^b   Bayona, Cristina ^c   Borrega, Pablo ^d   Gallegos Sancho, María I ^e   García Domínguez, Rocío ^f   de Portugal, Teresa ^g   Ramos Vázquez, Manuel ^h   Pérez Carrión, Ramón ⁱ   Bolós, María V ^j   Madero, Rosario ^a   Sánchez Navarro, Iker ^a   Fresno Vara, Juan A ^a   Arranz, Enrique Espinosa ^a,k  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b UNIVERSITY OF A CORUÑA   (Spain)

^c HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^d San Pedro de Alcántara Hospital   (Spain)

^e HOSPITAL GENERAL DE SEGOVIA   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^h Centro Oncologico de Galicia   (Spain)

ⁱ HOSPITAL QUIRÓN   (Spain)

^j PFIZER INC   (United States)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; SUNITINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE CONTROL; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

EID: 84871530565     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12734     Document Type: Article

References (53)

1. Cohen HT and McGovern FJ (2005). Renal-cell carcinoma. N Engl J Med 353,2477-2490.
2. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, and Crawford ED (2004). Cytoreductive nephrectomy in patients with metastatic renal cancer:a combined analysis. J Urol 171, 1071-1076.
3. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, and Brady MS(1998). Resection of metastatic renal cell carcinoma. J Clin Oncol 16, 2261-2266.
4. Motzer RJ, Bacik J, Murphy BA, Russo P, and Mazumdar M (2002). Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20, 289-296.
5. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, and Lasset C (2002). Prognostic factors of survival and rapid progressionin 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 13, 1460-1468.
6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27, 3584-3590.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007). Sunitinib versus interferonalfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115-124.
8. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28, 1061-1068.
9. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111.
10. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, et al. (2008). Bevacizumab plus interferonalfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26, 5422-5428.
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, et al. (2007). Temsirolimus, interferonalfa, or both for advanced renal-cell carcinoma. N Engl J Med 356, 2271-2281.
12. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, and Sorensen AG (2009). Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6, 327-338.
13. Tonini G, Fratto ME, Imperatori M, Pantano F, Vincenzi B, and Santini D (2011). Predictive factors of response to treatment in patients with metastatic renalcell carcinoma: new evidence. Expert Rev Anticancer Ther 11, 921-930.
14. Iorio MV and Croce CM (2009). MicroRNAs in cancer: small molecules with ahuge impact. J Clin Oncol 27, 5848-5856.
15. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, and Yousef GM (2010). Differential expression profiling of microRNAs and theirpotential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43, 150-158.
16. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et al. (2007). Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25, 387-392.
17. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, et al. (2009). MicroRNA profiling of clearcell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 13, 3918-3928.
18. Heinzelmann J, Henning B, Sanjmyatav J, Posorski N, Steiner T, Wunderlich H, Gajda MR, and Junker K (2011). Specific miRNA signatures are associated withmetastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29, 367-373.
19. Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet ML, Chomel JC, Guilhot F, Turhan AG, and Rasko JE (2010). Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica 95, 1325-1333.
20. Huber W, von Heydebreck A, Sultmann H, Poustka A, and Vingron M (2002).Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18(suppl.1), S96-S104.
21. Bühlmann P and Hothorn T (2007). Boosting algorithms: regularization, predic-tion and model fitting. Stat Sci 22, 477-505.
22. Hosmer DW and Lemeshow SA (1980). A goodness-of-fit test for the multiplelogistic regression model. Commun Stat A10, 1043-1069.
23. Harrell FE Jr, Lee KL, and Mark DB (1996). Multivariable prognostic models:issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15, 361-387.
24. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, andBukowski R (2005). Validation and extension of the Memorial Sloan-Ketteringprognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23, 832-841.
25. Sanchez-Navarro I, Gamez-Pozo A, Pinto A, Hardisson D, Madero R, Lopez R, San Jose B, Zamora P, Redondo A, Feliu J, et al. (2010). An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer. BMC Cancer 10, 336.
26. Dweep H, Sticht C, Pandey P, and Gretz N (2011). miRWalk-database: pre-diction of possible miRNA binding sites by walking the genes of three genomes. J Biomed Inform 44, 839-847.
27. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, and Narechania A (2003). PANTHER: a library of proteinfamilies and subfamilies indexed by function. Genome Res 13, 2129-2141.
28. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, et al. (2003). PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 31, 334-341.
29. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
30. Edgar R, Domrachev M, and Lash AE (2002). Gene expression omnibus: NCBIgene expression and hybridization array data repository. Nucleic Acids Res 30,207-210.
31. Motzer RJ, Bander NH, and Nanus DM (1996). Renal-cell carcinoma. N Engl JMed 335, 865-875.
32. Wang B, Howel P, Bruheim S, Ju J, Owen LB, Fodstad O, and Xi Y (2011).Systematic evaluation of three microRNA profiling platforms: microarray, beadsarray, and quantitative real-time PCR array. PLoS One 6, e17167.
33. Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, Figlin RA, Baum MS, and Motzer RJ (2011). Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103, 763-773.
34. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schoffski P, Barrascout E, Morel A, et al. (2011). Negative impact of bonemetastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22, 794-800.
35. Basappa NS, Elson P, Golshayan AR, Wood L, Garcia JA, Dreicer R, and Rini BI (2011). The impact of tumor burden characteristics in patients with meta-static renal cell carcinoma treated with sunitinib. Cancer 117, 1183-1189.
36. Terakawa T, Miyake H, Kusuda Y, and Fujisawa M (2011). Expression level ofvascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol. DOI:10.1016/j.urolonc.2011.1002.1012.
37. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, et al. (2009). Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27, 3312-3318.
38. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naimi B, Porcher R, de La Taille A, Menashi S, et al. (2010). Soluble isoforms of vascularendothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One 5, e10715.
39. Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, andCanipari C (2010). Predictive value of baseline serum vascular endothelial growthfactor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77, 809-815.
40. + progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer 104, 1144-1150.
41. Gruenwald V, Beutel G, Schuch-Jantsch S, Reuter C, Ivanyi P, Ganser A, andHaubitz M (2011). Circulating endothelial cells are an early predictor in renalcell carcinoma for tumor response to sunitinib. BMC Cancer 10, 695.
42. Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, et al. (2010). Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol 21, 1472-1481.
43. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, and Wessels JA (2011).Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17, 620-629.
44. Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, Guo C, Jin JM, Chen Z, Covarrubias M, et al. (2010). MicroRNA profiling of clear cell renal cell carcinomaby whole-genome small RNA deep sequencing of paired frozen and formalinfixed, paraffin-embedded tissue specimens. J Pathol 222, 41-51.
45. Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, and Teh BT (2009). MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 35, 109-114.
46. Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, Evans A, and Yousef GM (2011). Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59, 721-730.
47. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, and Wu X (2010). Geneticvariations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 31, 1805-1812.
48. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, Fabian P, Kren L, Michalek J, and Vyzula R (2010). Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29, 90.
49. Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, and Hanahan D (2009). MicroRNA dynamics in the stages oftumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23, 2152-2165.
50. Burczynski ME, Twine NC, Dukart G, Marshall B, Hidalgo M, Stadler WM, Logan T, Dutcher J, Hudes G, Trepicchio WL, et al. (2005). Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res 11, 1181-1189.
51. Twine NC, Stover JA, Marshall B, Dukart G, Hidalgo M, Stadler W, Logan T, Dutcher J, Hudes G, Dorner AJ, et al. (2003). Disease-associated expressionprofiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63, 6069-6075.
52. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, Muller SC, et al. (2011).MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6, e25787.
53. Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, and Kollmannsberger C (2009). A population-based study evaluating the impact ofsunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115, 776-783.